AR089506A1 - Un conjugado de glp-2 especifico del sitio que emplea un fragmento de inmunoglobulina - Google Patents
Un conjugado de glp-2 especifico del sitio que emplea un fragmento de inmunoglobulinaInfo
- Publication number
- AR089506A1 AR089506A1 ARP120105030A ARP120105030A AR089506A1 AR 089506 A1 AR089506 A1 AR 089506A1 AR P120105030 A ARP120105030 A AR P120105030A AR P120105030 A ARP120105030 A AR P120105030A AR 089506 A1 AR089506 A1 AR 089506A1
- Authority
- AR
- Argentina
- Prior art keywords
- glp
- conjugate
- intestinal
- gastrosis
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un conjugado del péptido tipo glucagón-2 (GLP-2) que comprende un GLP-2 nativo o un derivado del mismo y un fragmento de Fc de inmunoglobulina unidos de manera covalente por medio de un polímero no peptidilo, donde el GLP-2 nativo o un derivado del mismo tiene un grupo tiol que fue introducido por su extremo C-terminal, y un extremo del polímero no peptidilo está unido a un residuo de aminoácido del GLP-2 distinto del grupo amino N-terminal del mismo; un método para preparar el conjugado del GLP-2; una composición farmacéutica que comprende al mismo; y un método para tratar o prevenir una enfermedad intestinal, una lesión intestinal o gastrosis que comprende usar a la misma. Dado que el conjugado de GLP-2 de la presente tiene una afinidad de unión notablemente mayor por un receptor de GLP-2, presenta una vida media in vivo prolongada y una mayor durabilidad y estabilidad in vivo. Por consiguiente, el conjugado de GLP-2 de la presente se puede administrar a una dosis notablemente baja y presenta una mejora en el cumplimiento con la droga sin fluctuaciones en el nivel de glucosa en sangre. Por lo tanto, el conjugado de GLP-2 de acción prolongada de la presente se puede utilizar eficazmente para prevenir o tratar una enfermedad intestinal, una lesión intestinal o gastrosis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110147684A KR101895047B1 (ko) | 2011-12-30 | 2011-12-30 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089506A1 true AR089506A1 (es) | 2014-08-27 |
Family
ID=48698036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120105030A AR089506A1 (es) | 2011-12-30 | 2012-12-27 | Un conjugado de glp-2 especifico del sitio que emplea un fragmento de inmunoglobulina |
Country Status (9)
Country | Link |
---|---|
US (1) | US9504757B2 (es) |
EP (1) | EP2797621B1 (es) |
JP (1) | JP6131490B2 (es) |
KR (1) | KR101895047B1 (es) |
CN (2) | CN104144697A (es) |
AR (1) | AR089506A1 (es) |
ES (1) | ES2725805T3 (es) |
TW (1) | TWI666219B (es) |
WO (1) | WO2013100704A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
US9949927B2 (en) | 2012-04-10 | 2018-04-24 | The Regents Of The University Of California | Bis-polymer lipid-peptide conjugates and nanoparticles thereof |
EP3046586B1 (en) * | 2013-09-19 | 2021-07-07 | The Regents of The University of California | Methods of treatment using bis-polymer lipid-peptide conjugates and nanoparticles thereof |
US9994616B2 (en) | 2013-10-15 | 2018-06-12 | The University Of Tokyo | c-Met protein agonist |
CN106456589B (zh) | 2013-12-18 | 2020-07-07 | 斯克利普斯研究所 | 修饰的治疗剂、订合的肽脂质缀合物及其组合物 |
CN117065044A (zh) * | 2014-03-31 | 2023-11-17 | 韩美药品株式会社 | 通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法 |
KR101825048B1 (ko) | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
PT3481855T (pt) | 2016-07-11 | 2023-11-27 | Opko Biologics Ltd | Fator vii de coagulação de ação prolongada e métodos de produção do mesmo |
CN107987170B (zh) * | 2016-10-27 | 2018-12-18 | 浙江道尔生物科技有限公司 | 一种用于治疗肠道疾病的融合蛋白 |
KR102174436B1 (ko) * | 2017-08-17 | 2020-11-04 | 주식회사 엘지화학 | 불용성 안료 화합물의 정성분석방법 |
JP7249492B2 (ja) * | 2017-08-22 | 2023-03-31 | タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド | Glp-2融合ポリペプチドならびに消化管の状態を処置および予防するための使用 |
TWI794897B (zh) | 2017-09-28 | 2023-03-01 | 南韓商韓美藥品股份有限公司 | Glp-2衍生物之長效接合物 |
MX2020004620A (es) * | 2017-11-06 | 2020-10-12 | Shire Nps Pharmaceuticals Inc | Analogos y pepticuerpos de peptido 2 similar a glucagon (glp-2) para administracion antes, durante o despues de cirugia. |
US20210355187A1 (en) * | 2018-10-24 | 2021-11-18 | Shire-Nps Pharmaceuticals, Inc. | Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |
WO2020165900A1 (en) * | 2019-02-11 | 2020-08-20 | Opko Biologics Ltd. | Long-acting glp-2 analogs |
JP2023508175A (ja) * | 2019-12-24 | 2023-03-01 | ハンミ ファーマシューティカル カンパニー リミテッド | Glp-2又はその結合体を含む、代謝性骨疾患の予防又は治療用薬学的組成物 |
BR112022019518A2 (pt) * | 2020-04-03 | 2023-02-07 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica para prevenir ou tratar mucosite induzida por radioterapia, quimioterapia, ou uma combinação das mesmas, que compreende derivados de glp-2 ou um conjugado de atuação duradoura do mesmo |
CN111560062A (zh) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Elisiglutide的制备方法 |
WO2022159555A1 (en) * | 2021-01-20 | 2022-07-28 | The Trustees Of Columbia University In The City Of New York | Methods for treating graft-versus-host disease using glp-2 agonists and analogues thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
AU2002226897B2 (en) * | 2000-12-07 | 2007-10-25 | Eli Lilly And Company | GLP-1 fusion proteins |
EP1980572A1 (en) * | 2001-02-16 | 2008-10-15 | ConjuChem Biotechnologies Inc. | Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders |
CN1705681A (zh) * | 2002-10-14 | 2005-12-07 | 诺沃挪第克公司 | Glp-2化合物、制剂及其用途 |
US20070060512A1 (en) | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
AU2004282984B2 (en) * | 2003-11-13 | 2011-07-14 | Hanmi Science Co., Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
ES2380765T3 (es) | 2003-11-21 | 2012-05-18 | Nps Pharmaceuticals, Inc. | Producción del péptido 2 de tipo glucagón y análogos |
US20080207505A1 (en) | 2005-01-12 | 2008-08-28 | James Kenneth D | Bna Conjugates and Methods of Use |
DK1877435T4 (da) | 2005-05-04 | 2021-03-29 | Zealand Pharma As | Glucagon-lignende-peptid-2 (glp-2)-analoger |
AU2006321743A1 (en) * | 2005-10-24 | 2007-06-14 | Centocor, Inc. | GLP-2 mimetibodies, polypeptides, compositions, methods and uses |
JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
JP2012521360A (ja) * | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | Kv1.3の選択的かつ強力なペプチド阻害剤 |
ES2587397T3 (es) * | 2009-03-20 | 2016-10-24 | Hanmi Science Co., Ltd. | Procedimiento para preparar un conjugado específico de sitio de un polipéptido fisiológicamente activo |
KR101746686B1 (ko) * | 2010-10-26 | 2017-06-15 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체 |
-
2011
- 2011-12-30 KR KR1020110147684A patent/KR101895047B1/ko active IP Right Grant
-
2012
- 2012-12-27 AR ARP120105030A patent/AR089506A1/es unknown
- 2012-12-28 US US14/369,436 patent/US9504757B2/en active Active
- 2012-12-28 EP EP12861579.6A patent/EP2797621B1/en active Active
- 2012-12-28 CN CN201280071002.9A patent/CN104144697A/zh active Pending
- 2012-12-28 CN CN201910158317.0A patent/CN109810198B/zh active Active
- 2012-12-28 ES ES12861579T patent/ES2725805T3/es active Active
- 2012-12-28 WO PCT/KR2012/011748 patent/WO2013100704A1/en active Application Filing
- 2012-12-28 TW TW101150930A patent/TWI666219B/zh active
- 2012-12-28 JP JP2014550024A patent/JP6131490B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP2797621B1 (en) | 2019-03-06 |
JP6131490B2 (ja) | 2017-05-24 |
KR101895047B1 (ko) | 2018-09-06 |
TW201333032A (zh) | 2013-08-16 |
EP2797621A1 (en) | 2014-11-05 |
CN104144697A (zh) | 2014-11-12 |
CN109810198A (zh) | 2019-05-28 |
JP2015503554A (ja) | 2015-02-02 |
KR20130078634A (ko) | 2013-07-10 |
EP2797621A4 (en) | 2015-09-02 |
US20140377290A1 (en) | 2014-12-25 |
CN109810198B (zh) | 2023-06-06 |
US9504757B2 (en) | 2016-11-29 |
TWI666219B (zh) | 2019-07-21 |
ES2725805T3 (es) | 2019-09-27 |
WO2013100704A1 (en) | 2013-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR089506A1 (es) | Un conjugado de glp-2 especifico del sitio que emplea un fragmento de inmunoglobulina | |
AR081042A1 (es) | Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g | |
CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
AR071990A1 (es) | Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto | |
CN101432025B (zh) | 肽-肽酶抑制剂结合物及其使用方法 | |
CY1118373T1 (el) | Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος | |
ECSP19046865A (es) | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico | |
CY1118891T1 (el) | Συζευγμα ινσουλινης με χρηση θραυσματος ανοσοσφαιρινης | |
AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
BR112012004696B8 (pt) | composto modulador da atividade de tlr, seu uso, composição farmacêutica, medicamento, kit e combinação | |
UY33605A (es) | Profarmacos que comprenden un conjugado de conector de exendina | |
BRPI0814252B8 (pt) | composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia | |
MX2012008603A (es) | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. | |
EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
UY30659A1 (es) | Grupo de compuestos de benzoilamino heterociclico, composiciones farmacéuticas, porcesos para su preparacion y aplicaciones. | |
PE20120514A1 (es) | Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica | |
EA201290722A1 (ru) | Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение | |
AR100695A1 (es) | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón | |
BR112012027759A2 (pt) | Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso | |
BR112015013183A2 (pt) | proteínas de fusão para uso como aperfeiçoadores imunogênicos para indução de respostas de células t específicas para antígenos | |
DOP2014000083A (es) | Inmunoenlazadores dirigidos contra el tnf | |
AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
CN102202677A (zh) | 治疗疼痛的活性剂和方法 | |
BR112013000255A2 (pt) | ácidos hidróxifenil-hexinoicos substituídos por ariloxialquileno, método para preparação dos mesmos e seu uso dos mesmos como um medicamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |